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ABSTRACT Artemisinin combination therapies are considered the mainstay of ma-
laria treatment, but pediatric-friendly formulations for the treatment of infants are
scarce. We sought to evaluate the efﬁcacy and safety of a new dispersible-tablet for-
mulation of dihydroartemisinin/piperaquine phosphate (DHA/PQP) in comparison to
the marketed tablet (Eurartesim) in the treatment of infants with uncomplicated
Plasmodium falciparum malaria. Reported here are the results of a large phase II, ran-
domized, open-label, multicenter trial conducted in African infants (6 to 12 months
of age) from Mozambique, Burkina Faso, The Gambia, the Democratic Republic of
the Congo, and Tanzania. Primary efﬁcacy endpoint was the PCR-corrected adequate
clinical and parasitological response (ACPR) at day 28. Analysis was performed for
the intention-to-treat (ITT) and per-protocol (PP) populations. A total of 201 patients
received the dispersible-tablet formulation, and 99 received the conventional one
administered as crushed tablets. At day 28, the PCR-corrected ACPRs were 86.9%
(ITT) and 98.3% (PP) in the dispersible-tablet group and 84.9% (ITT) and 100% (PP) in
the crushed-tablet group. At day 42, these values were 85.9% (ITT) and 96.5% (PP) in
the dispersible-tablet group and 82.8% (ITT) and 96.4% (PP) in the crushed-tablet
group. The comparison between survival curves for time to new infections showed
no statistically signiﬁcant differences (P  0.409). The safety and tolerability proﬁle
for the two groups was similar in terms of type and frequency of adverse events
and was consistent with that expected in African infants with malaria. A standard
3-day treatment with the new dispersible DHA/PQP formulation is as efﬁcacious as
the currently used tablet in African infants and has a comparable safety proﬁle. (This
trial was registered at ClinicalTrials.gov under registration no. NCT01992900.)
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The last 15 years have witnessed impressive advances in the global ﬁght againstmalaria, including in sub-Saharan Africa, where the highest burden of morbidity
and mortality is still concentrated (1, 2). However, an estimated 429,000 malaria-
attributable deaths still occurred in 2016, the vast majority of which were among
African children, making it clear that major efforts are still required in the ﬁght against
this disease (3). One of the major threats in the global strategy against malaria is posed
by the emergence and potential spread of drug-resistant parasites. In response to this,
the World Health Organization (WHO) recommended in 2006 the use of artemisinin-
based combination therapies (ACTs) for the treatment of uncomplicated malaria (4).
The artemisinin derivatives are currently the most rapidly acting and potent antima-
larials (5). The pharmacodynamic effects of ACTs are due to the rapid absorption of
artemisinins and their strong activity against several stages of the malaria life cycle from
young asexual forms (rings) to early sexual forms (gametocytes) (6).
Eurartesim is a ﬁxed-dose combination composed of dihydroartemisinin (DHA) and
piperaquine phosphate (PQP) (7). This partner compound has a different mechanism of
action from that of artemisinins and a much longer half-life (several weeks), facilitating
the initial clearing of parasites, and a long posttreatment prophylactic effect (8, 9).
The efﬁcacy and safety of Eurartesim for the treatment of uncomplicated Plasmo-
dium falciparum malaria has been demonstrated in two phase III trials, respectively
conducted in 1,553 African children and 1150 Asian adults and children (10, 11). Both
studies demonstrated an equivalent efﬁcacy of DHA/PQP versus the comparative ACT.
In addition, they evidenced a superiority of DHA/PQP versus the comparative drugs in
a longer posttreatment prophylaxis period that suppress new infections from emerging
during follow-up.
In 2011, Eurartesim obtained a marketing approval by the European Medicine
Agency for all countries of the European Union, manufactured as ﬁlm-coated tablets
(12). The ACT was marketed for its use in children and adults and has been adopted by
several countries where malaria is endemic as the ﬁrst-line treatment of uncomplicated
malaria (3). Finally, Eurartesim obtained by the WHO the prequaliﬁcation status on 9
October 2015 (13).
One of the greatest challenges of malaria treatment is ensuring adequate intake and
compliance among young children, the population group most at risk of developing
life-threatening episodes (14). As of today, very few antimalarials are available in good
laboratory practice (GLP)-produced pediatric friendly formulations (15). Since infants
and very young children are generally unable to swallow oral tablets, Eurartesim was
administered in previous trials as an oral suspension of crushed tablets mixed with
water. However, the bitter taste of the crushed tablet could easily compromise toler-
ability in this age group, and crushing tablets is a suboptimal preparation procedure,
which could result in loss of drug and a reduced dose ingested. To overcome these
problems, a new water-dispersible tablet formulation of DHA/PQP was developed for
oral administration in infants and young children.
We present here the results of a multicenter trial in sub-Saharan Africa aiming to
assess the efﬁcacy, tolerability and safety of the new dispersible-tablet formulation of
DHA/PQP with respect to the marketed formulation, administered as a crushed tablet,
to infant patients (from 6 to 12 months of age) with uncomplicated P. falciparum
malaria. These results are part of a large phase II trial, which was designed to also collect
pharmacokinetic data for dispersible and crushed formulations of DHA/PQP in African
infants with malaria.
RESULTS
Patient disposition as presented in the case report forms is summarized in Fig. 1.
Overall, 443 patients were screened, and 300 were randomized: 201 to receive the
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dispersible-tablet formulation and 99 to receive the crushed-tablet formulation. How-
ever, two patients randomized in the dispersible-tablet group were excluded by all
analysis because one of them did not have parasites at day 0 (as determined by a
conﬁrmatory blood smear reading) and the other withdrew informed consent before
the ﬁrst drug administration (these patients, respectively, are reported as “other” and
“consent withdrawal” by day 28 in Fig. 1).
The most common reasons for study withdrawal were malaria recurrence (classiﬁed
as treatment failure) and informed consent withdrawal, occurring with a similar fre-
quency in both treatment groups. Repeated vomiting after drug administration was
more frequent in the dispersible arm compared to the crushed arm (5% versus 2%),
although such a difference was not statistically signiﬁcant (P 0.349 by the Fisher exact
test). Among patients reported as “other” in Fig. 1, one more patient in the dispersible-
tablet group dropped out due to family movement to a another area, while one patient
in the crushed-tablet group left the hospital after the ﬁrst study drug intake.
The number of patients enrolled in each country and their attribution to ITT and PP
populations are shown in Table 1. The patients excluded from the PP population due
to major protocol violations were 28 in the dispersible-tablet group (including the two
patients above described, who were also excluded from the ITT population) and 15 in
the crushed-tablet group (Table 2). All of them fulﬁlled the a priori declared major
violations or did not complete the study due to a reason different from malaria
recurrence or any other AE causing withdrawal from the study (i.e., consent withdrawal
or lost to follow-up). Two more patients were excluded from the PP population (one per
each treatment group) since it was not possible to assess their outcome on day 28 not
having the patients attended this visit and presenting malaria recurrence at day 42.
There were also seven randomized patients presenting baseline parasitemia outside the
range indicated in inclusion criteria, but all of these violations were judged as “minor”
FIG 1 Flow chart of study participants with uncomplicated P. falciparum malaria treated with a 3-day course of either dispersible or
crushed tablets of dihydroartemisinin-piperaquine (DHA/PQP). *, Two patients randomized in the dispersible treatment group were
excluded from all analysis due to unconﬁrmed malaria diagnosis at day 0 (classiﬁed as “Other”) and informed consent withdrawal before
ﬁrst study drug administration.
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by the Data Safety Monitoring Board (DSMB), and according to the study protocol these
patients were included in the PP population. Overall, there was a good balance for
demographic and baseline characteristics between treatment arms (Table 3).
Efﬁcacy outcomes. Both dispersible and crushed formulations were efﬁcacious.
Descriptive and inferential statistics for the cure rates are shown in Table 4 and efﬁcacy
results are summarized in Fig. 2. In the PP population, the PCR-corrected adequate
clinical parasitological responses (ACPRs) at day 28 were very high for both treatment
arms (98.3 and 100% for the dispersible and crushed groups, respectively), showing
homogeneity among cure rates with overlapping two-sided asymptotic conﬁdence
intervals (CI). Similarly, the PCR-uncorrected ACPR was comparable between treatment
arms and still above 90% for both groups. At day 42, the PCR-corrected ACPRs were
slightly lower than that observed at day 28 but remained very similar among treatment
arms (96.5 and 96.4% for the dispersible and crushed groups, respectively), whereas the
uncorrected ACPRs for the dispersible arm were to some extent higher with respect to
the crushed arm (76.3% versus 72.6%).
In the ITT population, the PCR-corrected ACPRs at day 28 were indeed similar
between treatment arms (86.9 and 84.9% for the dispersible and crushed groups,
respectively), while the uncorrected ACPRs were nearly identical (80.9 and 80.8%). At
day 42, the PCR-corrected ACPRs were to some extent lower than those observed at day
28 for both arms (Fig. 2). Similar to the ﬁndings observed in the PP population, the
uncorrected ACPRs in the ITT population for the dispersible-tablet group were slightly
higher with respect to the cure rate for the crushed-tablet group. Overall, for both
PCR-corrected and uncorrected ACPRs, the asymptotic 95% CI values showed a good
homogeneity with overlapping values and including the zero value for the computed
differences (Table 4). Considering both ITT and PP populations overall, the comparison
TABLE 1 Patient accountability by country in ITT and PP populationsa
Study population
DHA/PQP dispersible-tablet
group
DHA/PQP crushed-tablet
group
ITT PP ITT PP
n % n % n % n %
Total 199 100 173 100 99 100 84 100
Mozambique 90 45.2 83 48.0 51 51.5 40 47.6
Gambia 11 5.5 6 3.5 3 3.0 3 3.6
DR-Congo 26 13.1 25 14.5 7 7.1 7 8.3
Burkina Faso 67 33.7 57 33.0 37 37.4 33 39.3
Tanzania 5 2.51 2 1.2 1 1.0 1 1.2
an, number of patients. DR-Congo, Democratic Republic of the Congo.
TABLE 2 Summary of major protocol violations
Category
DHA/PQP treatment group
Dispersible tablet
(n  199)
Crushed tablet
(n  99)
Total no. of patients with major violations 26 15
% of patients with major violations 13.1 15.2
Protocol violation, no. (%) of patients
Repeated study drug vomiting 10 (5.0) 2 (2.0)
Study drug noncompliance 2 (1.0) 0
Presence of jaundice at screening 1 (0.5) 0
Consent withdrawal 3 (1.5) 8 (8.0)
Visit at day 28 not performed and malaria
recurrence at day 42
1 (0.5) 1 (1.0)
Lost to follow-up at or before day 42 8 (4.0) 3 (3.0)
Moved away from the study site 1 (0.5) 0
Left the hospital after ﬁrst drug administration 0 1 (1.0)
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between the dispersible and crushed groups for the corrected and uncorrected ACPRs,
assessed at day 28 or 42, showed no statistically signiﬁcant differences.
The occurrence of malaria recurrences by time points, as well as other reasons for
treatment failure, are shown in Table 5. At day 28, the numbers of new infections were
similar between the treatment arms (6 and 4% for the dispersible and crushed groups,
respectively), whereas only two recrudescences occurred in the dispersible-tablet
group. By day 42, the proportion of patients experiencing new clinical malaria episodes
increased similarly in both dispersible and crushed groups (ITT population), reaching,
respectively, 18.1 and 21.2% of the new infections (P  0.519 [chi-square test]) and 2.5
and 1.0% of recrudescences (P  0.667 [Fisher exact test]). When estimated by
Kaplan-Meier survival analysis, the cumulative risks of new infection at day 42 were 19.8
and 23.6% for the dispersible and crushed groups, respectively (Fig. 3), whereas those
for recrudescence were 3.1 and 1.3% (ITT population). Similar results were obtained for
the PP population (data not shown). As for the cure rates, comparison by log-rank tests
between treatment groups on time to new infection and time to recrudescence was not
statistically signiﬁcant in both ITT and PP populations (i.e., new infections, P  0.409
and P  0.568, respectively; recrudescences, P  0.404 and P  0.162, respectively).
One ETF occurred during the study due to the evolution of uncomplicated into
severe malaria in a patient enrolled 2 days after initial malaria symptoms. The compli-
cation occurred 20 h after the ﬁrst study drug intake and was probably due to the late
starting of antimalarial treatment. At day 42, the overall proportions of treatment
TABLE 3 Demographic and baseline characteristics (ITT population)
Characteristic
DHA/PQP treatment group
Dispersible tablet
(n  199)
Crushed tablet
(n  99)
No. (%) of patients
Male 89 (44.7) 47 (47.5)
Female 110 (55.3) 52 (52.5)
Mean age and wt  SD
Age (mo) 9.1 1.8 9.2 2.0
Wt (kg) 7.9 1.2 8.0 1.1
Clinical data
Fever, no. (%) of patients 119 (59.8) 61 (61.6)
Mean temp in °C (range) 37.8 (35.8–40.3) 37.8 (35.8–40.2)
Mean parasite density (range) 53,282 (771–226,707) 56,480 (108–322,194)
Presence of gametocytes, no. (%) of patients 10 (5.0) 5 (5.1)
Mean hemoglobin in g/dl (range) 8.96 (5.40–12.00) 8.98 (6.90–12.40)
TABLE 4 PCR-corrected and uncorrected adequate clinical and parasitological response by time points in ITT and PP populations
Study populationb Cure rate (ACPR)
No. (%) of patients in DHA/PQP
treatment group
Treatment difference (DHA/PQP dispersible–
DHA/PQP crushed)
Dispersible table Crushed tablet  (%)
Two-sided 95% CIa
Without CC With CC
Day 28
ITT (n  199, 99) PCR corrected 173 (86.9) 84 (84.9) 2.08 0.064–0.106 0.071–0.113
Uncorrected 161 (80.9) 80 (80.8) 0.09 0.094–0.096 0.101–0.103
PP (n  173, 84) PCR corrected 170 (98.3) 84 (100) 1.73 0.037–0.002 0.046–0.011
Uncorrected 158 (91.3) 80 (95.2) 3.91 0.101–0.023 0.110–0.032
Day 42
ITT (n  199, 99) PCR corrected 171 (85.9) 82 (82.8) 3.10 0.058–0.120 0.065–0.127
Uncorrected 135 (67.8) 61 (61.6) 6.22 0.053–0.178 0.061–0.186
PP (n  173, 84) PCR corrected 167 (96.5) 81 (96.4) 0.10 0.047–0.049 0.056–0.058
Uncorrected 132 (76.3) 61 (72.6) 3.68 0.078–0.151 0.087–0.160
aCI, conﬁdence interval; CC, continuity correction.
bNumbers in parentheses correspond to the numbers of individuals treated with the dispersible tablet and the crushed tablet, respectively.
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failures (ETFs plus LTFs) were similar between the treatment arms, corresponding to 42
cases (21.1%) in the dispersible-tablet group and 22 cases (22.2%) in the crushed-tablet
group (P  0.825 [chi-square test]; ITT population).
Parasite clearance was rapid in both treatment arms. In the ITT population, fewer
than half of the patients were parasitemic at day 1 (46.2 and 48.5% in the dispersible
and crushed groups, respectively), with only few of them remaining parasitemic at day
2 (3.0% versus 2.0%). With the exception of one patient who was still parasitemic up to
day 7 (dispersible-tablet group), all other patients were aparasitemic by day 3. No
statistically signiﬁcant differences in parasitemia clearance between treatment groups
were found using the log-rank test (P  0.653).
At baseline, about 60% of the patients had fever. At day 2, more than 96% of the
patients were afebrile in both groups. Upon enrollment, only 5% of the patients in both
groups presented gametocytes, which quickly disappeared in the ﬁrst few days. Ga-
FIG 2 ACPR at days 28 and 42 of treatment with dispersible and crushed DHA/PQP formulations administered to infant patients with
uncomplicated P. falciparum malaria.
TABLE 5 Treatment failure by time point (ITT population)
Reason for failure
No. and % of patients in each treatment group
Day 28 Day 42
Dispersible
tablet
(n  199)
Crushed
tablet
(n  99)
Dispersible
tablet
(n  199)
Crushed
tablet
(n  99)
n % n % n % n %
Recrudescencea 2 1.0 0 0.0 5 2.5 1 1.0
New P. falciparum infection 12 6.0 4 4.0 36 18.1 21 21.2
Early treatment failure (ETF) 1 0.5 0 0.0 1 0.6 0 0.0
Late treatment failure (LTF) 14 7.0 4 4.0 41 20.6 22 22.2
Late clinical failure (LCF) 3 1.5 2 2.0 18 9.1 12 12.1
Late parasitological failure (LPF) 11 5.5 2 2.0 23 11.6 10 10.1
Lost to follow-up 8 4.0 3 3.0 8 0.0 4 1.0
Repeated vomiting 10 5.0 2 2.0 10 5.0 2 2.0
Withdrawal before the time of
analysis (day 28): any reason
except lost to follow-up
4 2.0 9 9.1 4 2.0 9 9.1
Day 28 visit missing and
parasitemia at day 42
1 0.5 1 1.0 - - - -
Adverse event 0 0.0 0 0.0 0 0.0 1 1.0
Total no. of failures 38 19.0 19 19.2 64 32.2 38 38.4
aFor two patients (one for each group) with malaria recurrence, PCR analysis was not performed. Therefore,
DSMB categorized these patients as treatment failures in the ITT population and missing in the PP
population.
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metocytes did not develop during the course of the study. Due to the quick disap-
pearance of fever and the gametocytes, the corresponding survival analyses were not
performed.
Safety results. Both DHA/PQP formulations were well tolerated, with most AEs of
mild or moderate severity. The AE proﬁles for both treatment groups were similar in
terms of the type and frequency of events. Totals of 160 (80.4%) and 84 (84.9%)
patients, respectively, treated with the dispersible or crushed formulations, had at least
one AE during the study. Anemia, vomiting, diarrhea, rhinitis, and cough were the most
frequently reported AEs and were often associated with malaria, inﬂuenza, and respi-
ratory tract infections. The occurrence of laboratory AEs, e.g., altered liver enzymes
(AST), was very rare and was similar between the treatment groups.
The proportion of patients experiencing at least one treatment-emergent adverse
event (TEAE), for which the relationship with the study drug was suspected, was slightly
more prevalent in patients treated with the crushed-tablet formulation than in patients
treated with the dispersible-tablet formulation (42.4% versus 33.7%, P  0.139 [chi-
square test]) (Table 6). In particular, gastrointestinal tolerability was better for patients
treated with the dispersible-tablet formulation since vomiting occurred less frequently
in this group compared to the crushed-tablet group (22.6% versus 31.3%, P  0.105
[chi-square test]). Cutaneous reactions were infrequent, with only one case of rash
(crushed group). One patient in the dispersible-tablet group developed moderate
anemia, which occurred 1 week after treatment and resolved 3 weeks later. Overall,
none of the TEAEs required hospitalization.
There were no signiﬁcant differences between treatment groups in ECG parameters
at baseline and during follow-up. A relevant and comparable reduction of HR (heart
rate) in both treatment groups was observed at day 2 and at day 7. Related with this
reduction, an increase in PR, QT, and QTcF intervals was observed in both groups
with a comparable extension. A change in QTcF interval from baseline was detect-
able at day 2 predose and increased after drug administration, with 22 patients in
the dispersible-tablet group (11.1%) and 14 patients in the crushed-tablet group
(14.1%) manifesting a QTcF prolongation over 60 ms, none of which included
FIG 3 Time to new infections: survival analysis. A Kaplan-Meyer curve shows the cumulative risk of developing new infections in infants
(ITT population) treated with either a dispersible- or a crushed-tablet formulation during a 42-day follow-up period.
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clinical translation. No cases of QTcF prolongation higher than 500 ms were
reported. At day 7, the QTcF prolongation tended to normalization, with only one
patient in the dispersible-tablet group and two patients in the crushed-tablet group
still maintaining QTcF prolongation. Overall, no arrhythmias or any other cardio-
vascular AEs were reported.
Two severe adverse events (SAEs) occurred during the study, both judged unrelated
to the study treatment. The ﬁrst SAE involved the death of a 6-month-old male patient
enrolled in the crushed-tablet group. He received the full treatment course and was
discharged from the hospital after malaria resolution (day 3). At day 27, the child was
seen as an outpatient in a peripheral health post, with a history of fever, cough, and
diarrhea. After a positive rapid diagnostic test for malaria, he was treated with arte-
mether/lumefantrine. However, a malaria diagnosis was not conﬁrmed by microscopy,
and 2 days later the mother reported the child’s death. The investigator considered
sepsis the most likely cause of death (a diagnosis supported by a verbal autopsy). The
second SAE occurred in a male of 11 months enrolled in the dispersible-tablet group.
He received the ﬁrst dose of the study drug, and 20 h later the patient condition
deteriorated, with evidence of severe anemia (hemoglobin, 4.9 g/dl) and polypnea. The
study treatment was interrupted, and the patient received parenteral quinine for
malaria and blood transfusion for anemia. After 4 days of hospitalization, followed by
oral treatment with quinine for a further 5 days, the event was resolved.
TABLE 6 Treatment-emergent adverse events suspected to be related to the study
treatment administration (ITT population)
System organ class and preferred term
No. and % of patients in each
DHA/PQP treatment group
Dispersible
tablet
(n  199)
Crushed
tablet
(n  99)
n % n %
Patient with at least one TEAEa 67 33.7 42 42.4
Blood and lymphatic system disorders
Anemia 1 0.5 0 0.0
Thrombocytosis 1 0.5 0 0.0
Gastrointestinal disorders
Diarrhea 0 0.0 2 2.0
Vomiting 45 22.6 31 31.3
Nausea 1 0.5 0 0.0
Salivary hypersecretion 3 1.5 1 1.0
General disorders and administration site conditions
Pyrexia 0 0.0 1 1.0
Infections and infestations
Gastroenteritis 1 0.5 2 2.0
Malaria 1 0.5 0 0.0
Investigations
Electrocardiogram QTcF prolonged (60 ms) 23 11.6 15 15.2
Metabolism and nutrition disorders
Decreased appetite 1 0.5 1 1.0
Respiratory, thoracic, and mediastinal disorders
Cough 1 0.5 0 0.0
Skin and subcutaneous tissue disorders
Papulosquamous rash 0 0.0 1 1.0
aTEAE, treatment-emergent adverse event.
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DISCUSSION
According to guidelines on the clinical investigation of medicinal products in a
pediatric population, there is a need to develop new formulations that allow accurate
dosing and enhance patient compliance in infants and young children (16). This
recommendation becomes even more necessary for the treatment of malaria, as young
children and infants are those most affected by the disease, and very few GMP-
produced pediatric-friendly formulations are available (15). Artemisinin-based combi-
nation therapy (ACT) is the current standard of care for patients with uncomplicated
malaria in Africa (4). ACTs are typically provided in tablet form, which can be challeng-
ing to administer to young children who are typically unable to swallow whole pills. To
facilitate the administration of ACTs to these individuals, tablets can be crushed and
mixed with water. However, this process can result in the loss of active ingredients and
lead to underdosing. In addition, crushed antimalarial tablets can be unpalatable since
they have a bitter taste causing children to spit them out, thus leading to uncertain
and/or subtherapeutic dosing (17).
Presently, there is only one ACT reported in the last updated version of the WHO
Model List of Essential Medicines for Children (last amended on August 2015), contain-
ing arthemether-lumefantrine, which was speciﬁcally developed as a dispersible for-
mulation to improve the effectiveness and accuracy of ACT dosing in infants and young
children (15). Thus, there is an urgent need to make available on the market other
pediatric formulations of different ACTs and, in this context, a new dispersible formu-
lation of the DHA/PQP ﬁxed-dose combination was developed for oral administration.
The dispersible-tablet formulation was similar in tolerability, efﬁcacy, and safety to
the standard formulation administered as crushed tablet to infants with uncomplicated
P. falciparummalaria. In particular, PCR-corrected cure rates at day 28 of follow-up were
high for both formulations, and no differences were observed in the response to
treatment in terms of clearance of asexual parasites and fever, which were rapid in both
treatments groups. Follow-up periods longer than 28 days are currently recommended
by the WHO for antimalarial drugs with a long half-life (e.g., piperaquine or meﬂoquine)
to allow drug concentrations in the blood to fall below the minimum therapeutic
threshold (25). In fact, short observation periods can yield an underestimation of
recrudescence rates. Hence, analysis of cure rates on day 42 showed that they were still
high, suggesting a sustained efﬁcacy for both formulations. Furthermore, substantial
differences between the efﬁcacies of the two formulations were not observed for the
uncorrected ACPRs at day 42. Because the uncorrected cure rate is mainly affected by
new infections in high-transmission areas, this ﬁnding indicates a similar prophylactic
effect exerted by both formulations.
The present study conﬁrmed the satisfactory efﬁcacy of Eurartesim previously
obtained in phase III trials performed in Africa and Asia (7). In particular, the PCR-
corrected ACPR at day 28 or the incidence of recurrences were similar to that obtained
in African children (10).
The dispersible formulation was well tolerated, and its safety proﬁle was comparable
to the crushed tablet. No new safety issues arose from the present study, and all
ﬁndings were in line with the former ones. Most of the commonly reported AEs were
symptoms of malaria. Similarly, the pattern of changes in laboratory variables was
consistent with acute malaria and its resolution, with no differences between treatment
groups. The most common drug-related AE was vomiting, and the corresponding
frequency was similar to that previously reported in African children treated with
crushed or uncrushed tablets (10). Importantly, no arrhythmias or other cardiovascular
events were reported during the study. QTcF interval prolongations (difference from
baseline higher than 60 ms) were observed in 11.6 and 15.2% of patients in the
dispersible and crushed groups, respectively (P  0.381 [chi-square test]). Prolongation
of the QT interval was assessed using both Fridericia’s and Bazett’s correction methods
but, notably, both formulas could be biased by the physiological high HR present in
infants and exacerbated by the ill status and fever. In fact, baseline evaluations differed
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drastically (by 60 ms) when the different correction methods were applied. The
reduction in HR observed after drug administration could also induce a bias in the
estimation of QTc. Accordingly, QTcF recorded at the screening visit was lower than
that recorded at day 7 (335  16 ms versus 410  22 ms), when malaria was resolved
and the blood level of piperaquine was below the concentration considered relevant
for sustaining QT interval prolongation. These considerations suggest that the QTcF
assessment in infants by DHA/PQP could be overestimated. Nonetheless, QTcF never
exceeded the normal limits (450 to 470 ms), no cases evolved in rhythm disturbance,
and all of the changes observed during therapy were never associated with clinical
signs of cardiotoxicity.
Dispersible tablets are expected to contribute to ease of drug administration in
subjects having difﬁculties in swallowing whole tablets, i.e., infants and young children.
Since the dispersible formulations were similar in efﬁcacy and safety to the conven-
tional formulation in the infant population, we believe that this highly efﬁcacious
formulation should be made more readily available to all children below 5 years of age.
Cost savings are also likely with its use, with the potential beneﬁt of improving the
acceptability of the combination once available on the market. It is noteworthy that a
recent cost-effectiveness analysis of DHA/PQP for ﬁrst-line treatment of uncomplicated
malaria in African children showed that the use of this ACT, particularly in areas with
moderate to high malaria transmission, is clearly justiﬁable from both clinical and
economic perspectives (18, 19).
The results presented here are part of a large study that was designed to evaluate
also the population pharmacokinetics of piperaquine and dihydroartemisinin in African
infants, since it appears important to demonstrate bioequivalence of the new formu-
lation on PK grounds once similar efﬁcacy and safety have been conﬁrmed. The new
dispersible formulation of Eurartesim is easy and safe to administer and provides better
grounds for an enhanced compliance and effective treatment; hence, this should
facilitate drug registration by Regulatory Authorities, prequaliﬁcation by the WHO and,
ﬁnally, full adoption in malaria control programs. Further studies are needed to clearly
establish the improvement of the new formulation on compliance, hoping that the
simplicity of its administration will improve substantially the adherence to the full 3-day
course of treatment, therefore impacting the reduction of malaria morbidity and
mortality in infants and young children and minimizing parasite resistance to ACTs.
MATERIALS AND METHODS
Study design. Between November 2013 and June 2015, a phase II, randomized, open-label, multi-
center trial was performed in seven sites of ﬁve African countries: Centro de Investigação em Saude da
Manhiça, Maputo, Mozambique; Kinshasa School of Public Health, University of Kinshasa, Democratic
Republic of the Congo; Centre Muraz Bobo-Dioulasso, Nanoro, Burkina Faso; Centre National de Recher-
che et de Formation en Paludisme, Ouagadougou, Burkina Faso; Ifakara Health Institute, Bagamoyo,
Tanzania; National Institute for Medical Research, Korogwe, Tanzania; and Medical Research Council Unit,
The Gambia.
The study protocol was approved by the Institutional Review Board of the Hospital Clínic of Barcelona
(Spain) and by the National Ethics Review Committee and/or Institutional Review Board at each trial site.
The trial was conducted under the provisions of the Declaration of Helsinki and in accordance with GCP
guidelines (20, 21). A data safety monitoring board (DSMB) was established, working independently, to
harmonize and monitor patients’ safety. The trial was registered in the ClinicalTrial.gov registry under
registration no. NCT01992900 on 4 September 2014.
Patients. A targeted number of 300 infants (male and female) with uncomplicated malaria were
enrolled in the study. Since the study was designed to evaluate also the population pharmacokinetics of
piperaquine and dihydroartemisinin in African infants, the sample size has been estimated on the basis
of previous PK studies (22, 23), and all efﬁcacy and safety analyses are descriptive, including the P values
and conﬁdence intervals. The inclusion criteria were age 6 to 12 months, a body weight of 5 kg, a P.
falciparum monoinfection with asexual parasite densities between 1,000 and 200,000 parasites/l of
blood, fever (axillary temperature of 37.5°C), or a history of fever in the preceding 48 h. Exclusion
criteria were previous treatment with antimalarials, acute malnutrition, severe malaria, danger signs,
moderate/severe anemia (Hb  7 g/dl), a family history of sudden death or known congenital prolon-
gation of the QT interval, or treatment with QT prolongation inducers or strong cytochrome-P450
inhibitors/inducers or antiretroviral drugs (or lactated by HIV-positive women under antiretroviral
therapy). Patients satisfying the inclusion and exclusion requirements were enrolled if the parent or
guardian signed a written informed consent.
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Randomization and masking. Randomization was centralized using an interactive web-based
response system. A randomization list was generated by an independent contract research organization
(CROS NT, Italy), with each treatment allocation concealed in sealed opaque envelopes that were opened
by the investigators only after patient randomization. An allocation ratio of 2:1 (dispersible versus
crushed formulation) was applied, balancing patients for sex, to recruit 200 patients to receive the
dispersible DHA/PQP formulation and 100 patients to receive the marketed tablet. No stratiﬁcation for
countries or sites was applied.
Procedures. The DHA/PQP dispersible formulation was a coformulated, water-dispersible ﬂat tablet,
provided in two different strength dosages: 10/80 mg and 20/160 mg of dihydroartemisinin/piperaquine
tetraphosphate (as cellulose-microencapsulated piperaquine tetraphosphate) and other components
(cellulose, starch, croscarmellose, black cherry ﬂavor, saccharine, sucrose, and magnesium stearate). The
marketed Eurartesim formulation was a coformulated, ﬁlm-coated tablet, provided in one strength of
20/160 mg of DHA/PQP (Sigma-Tau, Italy) (12). Both formulations were administered once a day for three
consecutive days, according to body weight. Patients weighing 5 to 7 kg received a daily dose of 10/80
mg of DHA/PQP, while patients weighing 7 kg to 13 kg received a daily dose of 20/160 mg of
DHA/PQP.
DHA/PQP administration has a food interaction effect resulting in an increase of piperaquine
absorption when concomitantly administered with high-fat food (23). To reduce this effect, the ﬁrst dose
was administered as soon as randomization was done, and deliberate efforts were made to ensure that
no food was administered in the following 3 h. For the other doses, patients should not have been fed
in the 3 h before drug intake and for the following 3 h. However, for infants needing food during the
restricted periods, this was limited to breast milk or a low-fat maize porridge.
Patients were kept at the health facility for the 3-day dosing period. Scheduled visits during follow-up
were at days 7, 14, 21, 28, and 42 posttreatment. In case of recurrent parasitemia, rescue treatment was
performed according to local guidelines.
The diagnosis of P. falciparum infection was made at each site by microscopy using standard
methods (24). Blood slides collected from screening until parasitemia clearance were also read by a
centralized laboratory (Centro de Investigaçao em Saúde da Manhiça, Maputo, Mozambique). If para-
sitemia recurred during the study, the distinction between recrudescence and new infection was made
by PCR genotyping (25). PCR analysis was centralized and performed under blind conditions at the
Institute of Tropical Medicine, Antwerp, Belgium. Three polymorphic markers (MSP1, MSP2, and GluRP)
were used to distinguish recrudescence from new infections. Recrudescence was deﬁned when at least
one identical allele for each marker was detected in the pre- and posttreatment samples. New infections
were deﬁned when all alleles for at least one marker differed between the two samples.
Blood samples for hematology and biochemistry were taken at enrollment and at day 7 and then
repeated at day 28 if clinically signiﬁcant abnormalities were detected at day 7 (analysis of main
hematological and biochemical parameters, assessed at days 0, 7, and 28 are summarized in Table S1 in
the supplemental material).
A 12-lead electrocardiogram (ECG) was recorded for each patient at enrollment (baseline) and then
repeated at day 2 before the last drug administration, as well as after 4 to 6 h of drug intake. An ECG was
also recorded at day 7 and repeated at day 28 if clinically relevant abnormalities were detected at day
7. All ECGs were digitalized using an ELI-150 cardiograph (Mortara Instruments Europe Srl, Italy), and ECG
reading and analysis were centralized by a cardiac laboratory (Cardiabase, Nancy, France).
Outcomes. The main efﬁcacy endpoint was the PCR-corrected adequate clinical parasitological
response (ACPR) at day 28. Other efﬁcacy and safety endpoints included the following: (i) day 28,
PCR-uncorrected ACPR; (ii) day 42, PCR-corrected and -uncorrected ACPR; (iii) the proportion of patients
with early and late treatment failure (ETF and LTF); (iv) asexual parasite density and clearance time; (v)
fever clearance time and gametocyte carriage over time; (vi) Kaplan-Maier survival analysis for new
infections and recrudescences over time; (vii) AE occurrence; and (viii) changes in hematology, blood
chemistry, vital signs, and ECG parameters.
Treatment outcome was assessed according to the study protocol and further revised by the DSMB
to complement the WHO in vivo efﬁcacy deﬁnitions (26). All cases not strictly matching these rules (e.g.,
patients having taken disallowed drugs or with partially missing data, such as blood parasitemia) were
evaluated under blind conditions at the DSMB meetings.
Statistical analysis. All statistical analyses were performed using the SAS system software,
version 9.2.
Analyses of efﬁcacy were performed for both the ITT and the PP populations, whereas safety analyses
were performed only for the ITT population. The ITT population included all patients taking at least one
dose of the study drug. The PP population included all randomized patients who received the full
treatment course, completed the day 28 assessment, had an evaluable PCR in case of recurrent
parasitemia, and did not meet major protocol violations (e.g., inclusion without a microscopically
conﬁrmed diagnosis or the occurrence of severe vomiting or severe malaria). Patients for whom the PCR
indicated a new infection were considered failures in the PCR-uncorrected analysis and successes in the
PCR-corrected analysis, whereas patients with PCR results indicating a recrudescence were counted as
failures in both analyses. Patients for whom the PCR result was not interpretable or missing or not done
were imputed as failures in the ITT population and excluded in the PP population. Patients lost to follow
up were excluded from the PP population (see Table S2 in the supplemental material).
The two-sided 95% conﬁdence interval (CI) for the treatment difference in the PCR-corrected and
uncorrected ACPRs at day 28 (or day 42) were generated using the normal approximation method (27).
The limits of the asymptotic CIs were computed. A CI with continuity correction was also computed to
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verify the robustness of the conclusions. Whenever the observed counts were small (i.e., not all cells had
observed counts of at least ﬁve) or there was a disagreement between the results of the two formulas
(with or without continuity correction), an exact CI was computed.
The proportion of aparasitemic patients was computed for each study visit by treatment group. The
parasite clearance time was deﬁned as the time elapsed between the ﬁrst study drug intake and the ﬁrst
of two consecutive evaluations with negative parasitemia. The proportion of afebrile patients was
computed at each study visit by treatment group. Early and late treatment failures were summarized by
proportion per each treatment group.
The cumulative risks of new infections and recrudescences were estimated through survival analysis
(Kaplan-Meier). In survival analyses of new infections, patients classiﬁed as new infections were consid-
ered as having reached the event, whereas patients who did not reach the event (i.e., subjects
withdrawing from the study or having a recrudescence or with an uninterpretable or missing PCR or
classiﬁed as a success) were censored at the relevant time. In survival analyses of recrudescences,
patients classiﬁed as recrudescence were considered to have reached the event, whereas patients who
did not reach the event (i.e., subjects withdrawing the study or with a new infection or with an
uninterpretable/missing PCR or classiﬁed as success) were censored at the relevant time.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.00596-17.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.1 MB.
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